Rasmus Holm-Jorgensen
Directeur Financier/CFO chez ACRIVON THERAPEUTICS, INC.
Fortune : 230 875 $ au 30/04/2024
Profil
Rasmus Holm-Jorgensen founded Kiniksa Pharmaceuticals Ltd.
in 2015, where he worked as Chief Strategy & Portfolio Officer from 2015 to 2022.
Mr. Holm-Jorgensen also currently works at Acrivon Therapeutics, Inc., as Chief Financial Officer from 2022.
Mr. Holm-Jorgensen also formerly worked at Synageva BioPharma Corp., as Group Vice President & General Manager from 2011 to 2015.
Mr. Holm-Jorgensen received his graduate degree from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/05/2024 | 27 258 ( 0,09% ) | 230 875 $ | 30/04/2024 |
Postes actifs de Rasmus Holm-Jorgensen
| Sociétés | Poste | Début |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Directeur Financier/CFO | 01/04/2022 |
Anciens postes connus de Rasmus Holm-Jorgensen
| Sociétés | Poste | Fin |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Fondateur | 01/04/2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2015 |
Formation de Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |